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Dual chamber (DOD) or "universal" pacemakers have
had a significant impact on the advancement of artificial
pacemakers by providing a more physiologic approach
to cardiac pacing. However, with the early generation
of DOD pacemakers (pacemakers that sense and pace in
both the atrium and the ventricle), a significant number
of patients experienced pacemaker-mediated tachy-
cardia because intact ventriculoatrial conduction was
sensed in the atrium and a reentrant tachycardia was
induced. Newer generation DOD pacemakers have pro-
vided longer atrial refractory periods, which should cor-
rect this problem.
The development of the "universal" dual chamber (DOD)
pacemaker, which is capable of sensing and pacing both the
atrium and the ventricle, has had a significant impact on
permanent cardiac pacing. This pacemaker offers many the-
oretical advantages and allows flexibility for the patient with
changing pacing needs. However, it adds significant com-
plexity to the analysis of normal and abnormal functions as
well as some potential specific problems, particularly the
problem of pacemaker-mediated tachycardia. Although the
theoretical potential for this was realized much earlier, the
actual clinical problem did not become relevant until in-
creasing numbers of patients had received a DOD or VDD
dual chamber pacemaker.
Our early experience (I) and the experience of others
(2-5) indicated that approximately 15% of patients with
early generation DDD pulse generators had pacemaker-me-
diated tachycardia; which is seen in patients with intact
ventriculoatrial (VA) conduction . This tachycardia occurs
because ventricular pacing results in retrograde atrial acti-
vation , which is sensed by the atrial sensing circuit as spon-
taneous atrial activity . The ODD pacemaker then paces the
ventricle after the atrioventricular (AV) interval in a tachy-
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In this study the first and second years of a 2 year
experience with DOD pacemakers were compared to de-
termine if the newer generation devices have allowed
maintenance of pacing in the DOD mode as opposed to
reprogramming to some alternate mode because of pace-
maker-mediated tachycardia or other pacing problems.
The results showed a significant decrease in pacemaker-
mediated tachycardia during the second year and con-
tinuation of pacing in the DOD mode in a higher percent
of patients. This improvement is attributed to improve-
ment in the pulse generator as well as better patient
selection.
cardia at the upper rate limit at which the pacemaker is
programmed. Because pacemaker-mediated tachycardia is
dependent on the presence and duration of VA conduction,
an alternative was developed to provide a pacemaker with
a longer atrial refractory period so that retrograde activity
would not be sensed. This, however, was not a program-
mable feature of the early DOD pulse generators, Therefore,
patients with early DOD units who experienced pacemaker-
mediated tachycardia often had to be programmed to an
alternate mode, DVI pacing (AV sequential pacing without
atrial sensing) in most, or VVI pacing (ventricular-inhibited)
in some.
The purpose of this analysis was to determine in second
and third generation DOD pacemakers with longer atrial
refractory periods and increased programming flexibility
(specifically with programmable atrial refractoriness) and
with better patient selection whether the incidence of pace-
maker-mediated tachycardia had decreased. In addition, we
evaluated whether pacing in the patient in whom a DOD
pacemaker had been implanted for DOD pacing was being
maintained in this mode .
Methods
Patient group. The first of our DOD devices was im-
planted under investigational guidelines in September 1981 .
We compared our experience during the first year (Septem-
ber 1981 to September 1982) with that during the second
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year (September 1982 to September 1983). During the first
year, 54 patients (group 1) received a pulse generator ca-
pable of DDD pacing. The 40 men and 14 women in this
group had a mean age of 65 years (range 21 to 89). During
the second year, 73 patients (group 2) received a unit capable
of DDD pacing. The 43 men and 30 women in this group
had a mean age of 59 years (range 7 to 82).
The pulse generators in the two groups differed. During
the first year, 47 patients received the Medtronic Versatrax
700017000A and 7 received the Cordis Gemini 415A (group
1). During the second year, 27 patients received the Med-
tronic Versatrax 7000I7000A, 29 received the Medtronic
Versatrax 7000A-235, 8 received the Cordis Gemini 415A
and 9 received the Cordis Sequicor 233F (group 2). The
programmable and nonprogrammable features of these pace-
makers are described in Table 1.
Indications forpacing. The indications for DDD pacing
evolved between the first and second year of DDD utili-
zation. In the first year, pacing was performed in 48% of
the patients for AV block, in 43% for sinus node dysfunction
and in 9% for diffuse conduction system disease. During
the second year, pacing was performed in 64% of the pa-
tients for AV block, in 15% for sinus node dysfunction, in
12% lor symptomatic carotid sinus hypersensitivity and in
9% for diffuse conduction system disease.
Follow-up. The mean follow-up period was 14.2 months
for group 1 and 5.4 months for group 2. During this period,
10 deaths occurred; all in group 1. None of the deaths was
related to pacemaker malfunction. Of the remaining 117
patients, 112 were followed up actively in our pacemaker
center and 5 were followed up elsewhere.
Results
At hospital discharge of group 1 patients, 34 (63%) were
undergoing pacing in the DDD mode and 20 (37%) in the
DVI mode. In group 2 at the time of discharge, 50 patients
(68%) were undergoing pacing in the DDD mode and 23
(32%) in the DVI mode. At follow-up for the entire group,
18 mode changes had been made: 12 (22%) in group 1 and
6 (8%) in group 2.
Pacemaker-induced tachycardia. A significant differ-
ence was seen in the incidence of pacemaker-mediated
tachycardia between the two groups: 12.9% in group 1 and
4.1 % in group 2 (p < 0.05). All three of the group 2 patients
in whom pacemaker-mediated tachycardia occurred had in-
traoperative assessment of VA conduction, and complete
VA block was documented in all three at the time of im-
plantation. Two of the three patients experienced pace-
maker-mediated tachycardia while hospitalized after pace-
maker implantation, and one developed pacemaker-mediated
tachycardia 1 month after implantation. All three of these
patients had received a Medtronic Versatrax 235 and all
underwent subsequent programming to the DVI mode. In
these patients, the surface electrocardiogram was not help-
ful; therefore, we can only state that the VA conduction
time was greater than 235 ms, which is the atrial refractory
period available in this pulse generator (Table 1).
Table 1. Programmable and Nonprograrnmable Features of Four Types of Pacemakers
Medtronic 7000I7000A Medtronic 7000A-235 Cordis 415A Cordis 233F
Lower rate (beats/min) 40 to 80 40 to 80 30 to 120* 30 to 120*
Atrioventricular delay (ms) 25 to 250 25 to 250 75 to 250 75 to 250
Upper rate (beats/min) 100, 125, 150, 175 100, 125, 150, 175 * *
Atrial pulse width (ms) 0.05, 0.1, 0.2, ... , 0.05, 0.1, 0.2, ... , 0.2, 0.3, 0.4, 0.5, 0.2, 0.3, 0.4, 0.5,
1.5 1.5 0.6, 0.8, 1.0, 2.0 0.6, 0.8, 1.0, 2.0
Ventricular pulse width (ms) 0.05, 0.1, 0.2, ... , 0.05, 0.1, 0.2, ... , 0.2, 0.3, 0.4, 0.5, 0.2, 0.3, 0.4, 0.5,
1.5 1.5 0.6, 0.8, 1.0, 2.0 0.6, 0.8, 1.0, 2.0
Atrial sensitivity (mV) 0.75, 1.5, 3.0 0.75, 1.5, 3.0 0.5, 1.3, 2.5 0.5, 1.3, 2.5
Ventricular sensitivity (mV) 2.5,5.0 2.5,5.0 0.5, 1.3, 2.5 0.5, 1.3, 2.5
Atrial refractory period (ms) 155 ms after sensed or Senses P waves or atrial 200, 250, 300, 350, 250, 300, 350, 400,
paced beat stimulus and lasts 400,500 500
until 235 ms after
sensed or paced
ventricular complex,
or begins with PVC
and lasts 340 ms
thereafter
Ventricular refractory period (ms) 235 235 ms after QRS on 200, 250, 300, 350, 250, 300, 350, 400,
last paced beat and 400,500 500
340 ms after PVC
Ventricular blanking period (ms) 12 12 39 to 47 39 to 47
*Upper rate limit determined by programmed atrial refractory period and atrioventricular delay. ... = and so forth, in that order; PVC = premature
ventricular complex.
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Pacemaker malfunction. Additional invasive and non-
invasive pacing changes were made (Table 2). Four patients
in group I required lead repositioning, whereas no patients
in group 2 did. Of the four patients who required lead
repositioning, two required repositioning of the atrial lead,
one because of atrial failure to capture and one because of
right diaphragmatic stimulation (neither of these problems
could be corrected noninvasively). The remaining two pa-
tients required repositioning of the ventricular lead, one
because of failure to capture and one because of failure to
sense (again, neither of these problems could be corrected
noninvasively). Failure to sense in the atrium occurred in
seven patients, and in all seven the problem was corrected
noninvasively by programming the atrial sensitivity from
the nominal value of 1.3 or 1.5 mV to their more sensitive
values of 0.5 to 0.75 mY, respectively. Muscle stimulation
was corrected noninvasively in three of four patients.
Two generators were explanted. One patient had an in-
fection that required removal of the entire system. In another
patient, the pacemaker remained fixed in the asynchronous
mode after a magnet was placed over the pacemaker. The
pacemaker was removed, and an identical pacemaker was
implanted. Evaluation of the explanted pulse generator re-
vealed a defect in the circuitry.
Fellow-up. At the time of follow-up in group I, pacing
was performed in the DDD mode in 26 patients (48%), in
the DVI mode in 24 (44%), in the VVI mode in 3 (5%)
and in the DOO mode (asynchronous AV sequential pacing)
in I (2%). This compares with patients in group 2, in whom
pacing was performed in the DDD mode in 47 (64%), in
the DVI mode in 23 (32%) and in the VVI mode in 3 (4%).
Discussion
Pacemaker-mediated tachycardia; role of extending
the atrial refractory period. The decrease in pacemaker-
mediated tachycardia between our first (group 1) and second
(group 2) year of experience with dual chamber (DDD)
pacing systems is striking. The reasons for this include better
patient selection, more complete intraoperative testing for
VA conduction and improvement in pulse generators with
longer or programmable (or both) atrial refractory periods.
With current pacemakers, we can extend the atrial refractory
period to as long as 600 ms and also have an additional
atrial refractory period extension that will occur after a pre-
mature ventricular complex. In one pacemaker utilized in
this experience, the longest atrial refractory period was 500
ms; in the other unit, the atrial refractory period extended
from a fixed atrial refractory period of 235 to 340 ms after
a premature ventricular complex (Table I). In our experi-
ence, pacemaker-mediated tachycardia has not occurred in
any patient who has had a pacemaker with a programmable
atrial refractory period. Of the 10 patients who have had
pacemaker-mediated tachycardia, 8 had a first generation
Table 2. Invasive and Noninvasive Pacing Changes in Two Groups of Patients
Year 1
(group I, 54 pts)
Year 2
(group 2. 73 pts)
Mode changes
Pacemaker model
Metronic 7000I7000A
Medtronic 7000A-235
Lead reposition
Atrial failure to sense
Corrected noninvasively
Muscle stimulation
Corrected noninvasively
Generator explant
Reason
Pacemaker-mediated tachycardia
Atrial failure to sense
Atrial failure to pace
Atrial failure to pace and sense
Atrial flutter
Control ventricular tachycardia
Muscle stimulation
Systemic infection
Subjective complaint
12
(12)
(0)
4
4
(4)
2
(2)
I
Pacemaker Mode Changes
Year 1 (group I)
DDD~ DVI (6 pts)
DDD~ VVI (I pt)
DDD~ DVI (I pt)
DVI ~ VVI (I pt)
DVI ~ DOO (I pt)
DDD~ VVI (I pt)
DVI ~ DDD (I pt)
6
(4)
(2)
o
3
(3)
2
(I)
1
Year 2 (group 2)
DDD~ DVI (3 pts)
DDD~ VVI (I pt)
DDD~ VVI (I pt)
DVI ~ VVI (I pt)
DDD = dual chamber pacemaker; DOO = asynchronous AV sequential pacing; DVI = atrioventricular sequential pacing without atrial sensing;
pts = patients; VVI = ventricular inhibited pacing.
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DDD pulse generator and 2 had a second generation DDD
pacemaker.
Extending the atrial refractory period may result in a
clinical trade-off because it does limit the upper rate limit
at which the patient can function. Although a concern, this
has not resulted in clinical problems for our patients. Al-
though we have seen the programmed upper rate limit ex-
ceeded in some patients who underwent exercise testing after
implantation, no patient has had any subjective complaints
of sudden limitations in exercise tolerance or other symp-
toms that could be attributed to exceeding the upper rate
limit during exercise.
Improved selection of patients for DDD pacing. In
addition to significantly decreased incidence of pacemaker-
mediated tachycardia, we are using the pacemakers more
effectively; 64% of our later group of patients (group 2)
remained in the DDD mode at follow-up compared with
only 48% of our initial patient group (group 1). Currently,
DDD pulse generators are more expensive and more com-
plex. Therefore, patients should be selected carefully as to
whether they would be able to utilize the DDD function
without developing problems. Indications for pacing in the
two groups changed significantly. In the first year, sinus
node dysfunction accounted for approximately 40% of pace-
maker implants, and in these patients, the frequency of intact
VA conduction is higher than that in patients with AV block.
In the second year, sinus node dysfunction accounted for
approximately 15% of pacemaker implants. Also, careful
patient selection, including evaluation of VA conduction
and increased pacemaker flexibility (that is, longer pro-
grammable atrial refractory periods), has allowed us to uti-
lize the technologic advances more completely.
Implications. Until pacemakers with DDD capability
are available at the same price as DVI or nonatrial sensing
noncommitted AV sequential pacing systems, one must con-
tinue to carefully assess the patient preoperatively for the
potential to develop pacemaker-mediated tachycardia. Even
though most instances of retrograde VA conduction can now
be remedied by systems with longer or programmable atrial
refractory periods, an occasional patient may have an ex-
tremely long VA conduction time not within the programm-
able limitation of the atrial refractory period. As was seen
in three of our patients, even if VA conduction is not present
before pacemaker implantation, this does not guarantee that
the patient will not have VA conduction at other times under
other physiologic conditions.
Improvements in second and third generation DDD pace-
makers have decreased the number of pacing problems.
Continued improvement in DDD technology should further
increase the applicability of DDD pacing.
We thank Kelly A. Griffin for her efforts in the preparationof the manuscript.
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